Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.56 |
| ▸ | AR | P10275 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | VCP | P55072 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14755578 | 0.83 | CYP19A1 (0.61) | KDM4ESMN1; SMN2RAB9ALMNACYP19A1 | |
| SCHEMBL956221 | 0.83 | ALDH1A1 (0.61) | KDM4ESMN1; SMN2RAB9ALMNAAR | |
| SCHEMBL4907429 | 0.79 | RAB9A (0.56) | KDM4ESMN1; SMN2RAB9AARKMT2A | |
| SCHEMBL21283206 | 0.79 | RAB9A (0.63) | KDM4ESMN1; SMN2RAB9ALMNAAR | |
| SCHEMBL534232 | 0.79 | CYP19A1 (0.41) | KDM4ESMN1; SMN2RAB9ALMNACYP19A1 | |
| SCHEMBL21283211 | 0.79 | CYP19A1 (0.45) | KDM4ESMN1; SMN2RAB9ALMNACYP19A1 | |
| SCHEMBL2493641 | 0.79 | ALOX5 (0.58) | KDM4ESMN1; SMN2RAB9ALMNAKMT2A | |
| SCHEMBL130198 | 0.76 | ALDH1A1 (0.69) | KDM4ESMN1; SMN2RAB9ALMNACYP19A1 | |
| SCHEMBL4283884 | 0.75 | KDM4E (1.00) | KDM4ESMN1; SMN2RAB9ALMNACYP19A1 | |
| SCHEMBL14755554 | 0.75 | CCR4 (0.48) | KDM4ESMN1; SMN2RAB9ALMNACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507776-B1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7119111-B2 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1507776-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | Amgen Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-0169502-B1 | 2-BENZYL-4-(2-MORPHOLINO)-4-PYRIOL) THIAZOLE | MERCK & CO. INC. (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4725606-A | AUTOIMMUNE DISEASES | MERCK & CO., INC. (US) | 1988-02-16 | — | — | US | disclosed |
| US-4697012-A | IMMUNOLOGY, ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1987-09-29 | — | — | US | disclosed |
| EP-0169502-A2 | 2-Benzyl-4-(2-morpholino)-4-Pyriol) Thiazole | MERCK & CO. INC. (US) | 1986-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | CASP3, BAX, BAD | KDM4E 1697/4885SMN1; SMN2 318/4885RAB9A 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.